Cagrilintide (CagriSema): dosage in studies
Not a recommendation, not treatment guidance. This page shows only what published human studies used, with sources. This site does not say how much anyone should use of any substance. Fimea warns against using injectable peptides bought online: Fimea warning.
Cagrilintide has been given to humans under the skin once a week, alone at 0.3-4.5 mg and together with semaglutide at 0.16-4.5 mg [1, 2]A.
In phase 3 trials the dose was 2.4 mg cagrilintide and 2.4 mg semaglutide once a week for 68 weeks, with the dose raised step by step [4, 5]A.
Doses used in studies
| Study | Participants | Dose | Frequency | Duration | Source and level |
|---|---|---|---|---|---|
| Enebo 2021 (phase 1b) | 96 adults, body-mass index 27.0-39.9 | 0.16, 0.30, 0.60, 1.2, 2.4 or 4.5 mg under the skin together with semaglutide 2.4 mg | Once a week | 20 weeks, 5 weeks of follow-up | [1]A |
| Lau 2021 (phase 2, dose-finding) | 706 adults without diabetes, overweight or obesity | 0.3, 0.6, 1.2, 2.4 or 4.5 mg under the skin; liraglutide 3.0 mg daily for comparison | Once a week | 26 weeks | [2]A |
| Frias 2023 (phase 2) | 92 adults with type 2 diabetes | 2.4 mg under the skin together with semaglutide 2.4 mg; comparison groups each alone at 2.4 mg | Once a week | 32 weeks | [3]A |
| REDEFINE 1, Garvey 2025 (phase 3) | 3,417 adults without diabetes | 2.4 mg under the skin together with semaglutide 2.4 mg | Once a week | 68 weeks | [4]A |
| REDEFINE 2, Davies 2025 (phase 3) | 1,206 adults with type 2 diabetes | 2.4 mg under the skin together with semaglutide 2.4 mg | Once a week | 68 weeks | [5]A |
| REIMAGINE 2, Buse 2026 (phase 3) | Type 2 diabetes, 30 countries | 2.4 mg + 2.4 mg or 1.0 mg + 1.0 mg (cagrilintide + semaglutide) under the skin | Once a week | 68 weeks | [6]A |
| Gabe 2024 (QT study) | 105 healthy participants | Dose raised to 4.5 mg under the skin | Once a week | QT measurements 12-72 hours after the last dose | [7]A |
| Nielsen 2026 (kidney and liver) | 33 and 32 adults with varying kidney or liver function | 0.6 mg or 0.9 mg under the skin | Single dose | Follow-up 36-39 days | [8]A |
Evidence levels: A = randomised human trial or meta-analysis · B = observational human study or case series · C = animal study · D = cell or laboratory study · E = not peer-reviewed
Notes
In the repeated-dose trials the dose was raised step by step over several weeks, and participants were screened [1, 4]A. The kidney and liver studies gave a single dose [8]A.
Nearly all recent trials concern the fixed combination with semaglutide (CagriSema), not cagrilintide alone [4, 5, 6]A.
What points the other way or is uncertain
Adverse events became more common as the dose rose: in the phase 2 trial, 41-63 percent of those on cagrilintide reported gastrointestinal adverse events against 32 percent on placebo [2]A. With the combination in REDEFINE 1, the shares were 79.6 and 39.9 percent [4]A.
Cagrilintide alone lowered HbA1c less than semaglutide, 0.9 against 1.8 percentage points [3]A.
- Cagrilintide (CagriSema): the full substance page
- Cagrilintide: reconstitution and unit calculator
- Are peptides legal in Finland?
- All dose pages and calculators
Read the research yourself: sources
- Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397:1736-1748. PMID 33894838
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398:2160-2172. PMID 34798060
- Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402:720-730. PMID 37364590
- Garvey WT, et al; REDEFINE 1 Study Group. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393:635-647. PMID 40544433
- Davies MJ, et al; REDEFINE 2 Study Group. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393:648-659. PMID 40544432
- Buse JB, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026;14:662-677. PMID 42251859
- Gabe MBN, et al. Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants. Diabetes Obes Metab. 2024;26:5805-5811. PMID 39279639
- Nielsen MJF, et al. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. Clin Pharmacokinet. 2026;65:1087-1099. PMID 42228334
Dose details are as given in the abstracts of the publications. Reference details checked in PubMed on 14 Oct 2026.
Content is general information about research, not medical advice. If you have symptoms, contact a healthcare professional.